Biotech drugmaker Amgen Inc. said a federal court has enforced a preliminary injunction barring Roche from launching an anemia drug that would compete against its products.
Amgen makes the anemia drugs Epogen and Aranesp, which are blockbuster products used to control red blood cell levels in patients with anemia. Switzerland-based Roche makes Mircera.
The U.S. Court of Appeals for the Federal Circuit upheld a prior order by the U.S. District Court in Boston barring Roche from selling Mircera in the U.S. because a jury found the drug violated Amgen's patents.
Shares of Amgen Inc. closed down $1.68 at $48.58.
Amgen makes the anemia drugs Epogen and Aranesp, which are blockbuster products used to control red blood cell levels in patients with anemia. Switzerland-based Roche makes Mircera.
The U.S. Court of Appeals for the Federal Circuit upheld a prior order by the U.S. District Court in Boston barring Roche from selling Mircera in the U.S. because a jury found the drug violated Amgen's patents.
Shares of Amgen Inc. closed down $1.68 at $48.58.
0 comments:
Post a Comment